Abata Therapeutics has received Investigational New Drug (IND) clearance from the FDA for its first product candidate, ABA-101. The investigational new drug is aimed to help patients with progressive multiple sclerosis (MS).
ABA-101 is a patient-derived T cell receptor (TCR)-Treg cell therapy created specifically for patients with progressive MS who have imaging proof of ongoing inflammatory tissue injury and are human leukocyte antigen (HLA)-DRB1*15:01 positive, which is a major risk factor. The treatment works by genetically modifying a patient's regulatory T-cells (Tregs) so they can specifically recognize and react to immunogenic myelin fragments in the CNS.
Abata Therapeutics focuses on developing targeted therapies for autoimmune and inflammatory diseases using regulatory Treg technology. The company’s lead programs include treatments for progressive multiple sclerosis, type 1 diabetes, and inclusion body myositis. Its technology leverages Tregs to infiltrate, disrupt, and suppress inflammation at the disease site, offering targeted delivery.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.